74
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Prevention of COPD exacerbation by lysozyme: a double-blind, randomized, placebo-controlled study

, , , , , , & show all
Pages 831-838 | Published online: 21 Apr 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Takeo Ishii, Masaharu Nishimura, Asako Akimoto, Mark H James & Paul Jones. (2018) Understanding low COPD exacerbation rates in Japan: a review and comparison with other countries. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 3459-3471.
Read now

Articles from other publishers (3)

Francesco Nucera, Federica Lo Bello, Sj S. Shen, Paolo Ruggeri, Irene Coppolino, Antonino Di Stefano, Cristiana Stellato, Vincenzo Casolaro, Phil M. Hansbro, Ian M. Adcock & Gaetano Caramori. (2021) Role of Atypical Chemokines and Chemokine Receptors Pathways in the Pathogenesis of COPD. Current Medicinal Chemistry 28:13, pages 2577-2653.
Crossref
Phillippa Poole, Kavin Sathananthan & Rebecca Fortescue. (2019) Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2020:3.
Crossref
Marc Miravitlles, Anthony D’Urzo, Dave Singh & Vladimir Koblizek. (2016) Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. Respiratory Research 17:1.
Crossref